O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	25	prospective
O	26	31	study
O	32	34	of
B-intervention	35	46	endometrial
I-intervention	47	56	resection
O	57	59	to
O	60	67	prevent
B-condition	68	77	recurrent
I-condition	78	89	endometrial
I-condition	90	96	polyps
O	97	99	in
B-eligibility	100	105	women
I-eligibility	106	110	with
I-eligibility	111	117	breast
I-eligibility	118	124	cancer
I-eligibility	125	134	receiving
I-eligibility	135	144	tamoxifen
O	144	145	.

O	146	148	To
O	149	155	assess
O	156	159	the
O	160	164	role
O	165	167	of
O	168	179	endometrial
O	180	189	resection
O	190	192	in
O	193	203	preventing
O	204	214	recurrence
O	215	217	of
O	218	227	tamoxifen
O	227	228	-
O	228	238	associated
O	239	250	endometrial
O	251	257	polyps
O	258	260	in
O	261	266	women
O	267	271	with
O	272	278	breast
O	279	285	cancer
O	285	286	.

O	287	297	Randomized
O	297	298	,
O	299	310	prospective
O	311	316	study
O	317	318	(
B-ethinicity	318	326	Canadian
O	327	331	Task
O	332	337	Force
O	338	352	classification
O	353	354	I
O	354	355	)
O	355	356	.

O	357	365	Tertiary
O	366	376	university
O	376	377	-
O	377	387	affiliated
O	388	395	medical
O	396	402	center
O	402	403	.

B-total-participants	404	410	Twenty
O	411	422	consecutive
O	423	428	women
O	429	430	(
O	430	433	age
O	434	439	range
B-age	440	442	43
I-age	442	443	-
I-age	443	445	61
I-age	446	449	yrs
O	449	450	)
O	450	451	.

O	452	465	Hysteroscopic
O	466	473	removal
O	474	476	of
O	477	486	tamoxifen
O	486	487	-
O	487	497	associated
O	498	509	endometrial
O	510	516	polyps
O	517	521	with
O	522	524	or
O	525	532	without
O	533	545	simultaneous
O	546	555	resection
O	556	558	of
O	559	562	the
O	563	574	endometrium
O	574	575	.

O	576	584	Patients
O	585	589	were
O	590	600	randomized
O	601	603	to
O	604	611	undergo
O	612	613	(
B-intervention-participants	613	615	10
O	616	621	women
O	621	622	)
O	623	625	or
B-control	626	629	not
I-control	630	637	undergo
O	638	639	(
B-control-participants	639	641	10
O	641	642	)
O	643	654	concomitant
O	655	666	endometrial
O	667	676	resection
O	676	677	.

O	678	682	They
O	683	687	were
O	688	696	followed
O	697	700	for
O	701	703	at
O	704	709	least
O	710	712	18
O	713	719	months
O	720	721	(
O	721	726	range
O	727	729	18
O	729	730	-
O	730	732	24
O	733	735	mo
O	735	736	)
O	736	737	,
O	738	747	including
O	748	760	transvaginal
O	761	776	ultrasonography
O	777	782	every
O	783	784	6
O	785	791	months
O	792	795	and
O	796	808	hysteroscopy
O	809	813	when
O	814	825	endometrial
O	826	838	irregularity
O	839	842	was
O	843	848	noted
O	848	849	.

O	850	853	The
O	854	858	main
O	859	866	outcome
O	867	875	variable
O	876	879	was
B-outcome-Measure	880	890	recurrence
I-outcome-Measure	891	893	of
I-outcome-Measure	894	905	endometrial
I-outcome-Measure	906	912	polyps
O	912	913	;
B-outcome-Measure	914	924	occurrence
I-outcome-Measure	925	927	of
I-outcome-Measure	928	935	uterine
I-outcome-Measure	936	944	bleeding
O	945	948	was
O	949	953	also
O	954	959	noted
O	959	960	.

O	961	963	In
O	964	969	women
O	970	973	who
O	974	983	underwent
O	984	995	endometrial
O	996	1005	resection
O	1005	1006	,
O	1007	1011	only
B-iv-bin-abs	1012	1015	one
O	1016	1019	had
O	1020	1021	a
O	1022	1023	1
O	1024	1025	x
O	1026	1027	1
O	1027	1028	-
O	1028	1030	cm
B-outcome	1031	1042	endometrial
I-outcome	1043	1048	polyp
O	1049	1058	diagnosed
O	1059	1062	and
O	1063	1070	removed
O	1071	1077	during
O	1078	1084	follow
O	1084	1085	-
O	1085	1087	up
O	1087	1088	.

B-iv-bin-abs	1089	1094	Seven
O	1095	1100	women
O	1101	1109	remained
B-outcome	1110	1121	amenorrheic
O	1121	1122	,
O	1123	1126	and
B-iv-bin-abs	1127	1132	three
O	1133	1144	experienced
B-outcome	1145	1153	spotting
O	1154	1157	for
O	1158	1159	a
O	1160	1163	few
O	1164	1168	days
O	1169	1174	every
O	1175	1180	month
O	1180	1181	.

O	1182	1184	In
O	1185	1188	the
O	1189	1196	control
O	1197	1202	group
O	1202	1203	,
B-cv-bin-abs	1204	1207	six
O	1208	1213	women
O	1214	1217	had
B-outcome	1218	1227	recurrent
I-outcome	1228	1239	endometrial
I-outcome	1240	1246	polyps
I-outcome	1247	1256	requiring
I-outcome	1257	1270	hysteroscopic
I-outcome	1271	1278	removal
O	1279	1280	(
O	1280	1283	two
O	1283	1284	-
O	1284	1288	tail
O	1289	1295	Fisher
O	1295	1296	'
O	1296	1297	s
O	1298	1303	exact
O	1304	1308	test
O	1309	1310	p
O	1311	1312	<
O	1312	1313	0
O	1313	1314	.
O	1314	1316	06
O	1316	1317	)
O	1317	1318	.

O	1319	1329	Recurrence
O	1330	1332	of
O	1333	1344	endometrial
O	1345	1351	polyps
O	1351	1352	,
O	1353	1356	one
O	1357	1359	of
O	1360	1363	the
O	1364	1368	most
O	1369	1375	common
O	1376	1384	problems
O	1385	1387	in
O	1388	1396	patients
O	1397	1401	with
O	1402	1408	breast
O	1409	1415	cancer
O	1416	1425	receiving
O	1426	1430	long
O	1430	1431	-
O	1431	1435	term
O	1436	1445	treatment
O	1446	1450	with
O	1451	1460	tamoxifen
O	1460	1461	,
O	1462	1465	may
O	1466	1468	be
O	1469	1476	reduced
O	1477	1479	by
O	1480	1490	performing
O	1491	1502	endometrial
O	1503	1512	resection
O	1513	1515	at
O	1516	1519	the
O	1520	1524	time
O	1525	1527	of
O	1528	1541	hysteroscopic
O	1542	1549	removal
O	1550	1552	of
O	1553	1559	polyps
O	1559	1560	.

O	1561	1564	The
O	1565	1573	possible
O	1574	1578	risk
O	1579	1581	of
O	1582	1588	occult
O	1589	1600	endometrial
O	1601	1607	cancer
O	1608	1610	is
O	1611	1614	yet
O	1615	1617	to
O	1618	1620	be
O	1621	1631	determined
O	1631	1632	.

O	1633	1634	(
O	1634	1635	J
O	1636	1638	Am
O	1639	1644	Assoc
O	1645	1652	Gynecol
O	1653	1661	Laparosc
O	1662	1663	6
O	1663	1664	(
O	1664	1665	3
O	1665	1666	)
O	1666	1667	:
O	1667	1670	285
O	1670	1671	-
O	1671	1674	288
O	1674	1675	,
O	1676	1680	1999
O	1680	1681	)
